Inputs: momentum, trendVelocity
Momentum 21/100 with trend velocity 42/100 — trend is rolling over.
Prediction result · Ensemble engineUpdated 3:57 AM
AGIOAgios Pharmaceuticals, Inc. stock price outlook
$30.55-17.94% since prev closeBearish
Agios Pharmaceuticals, Inc. (AGIO) is trading at $30.55, down 17.94% since the previous close and -17.43% over the past week. Price sits below its 50-day average by 9.14%, with price momentum at 21/100 and trend velocity at 42/100. Sentiment across 8 recent headlines reads net constructive at 60/100. Volatility risk is elevated (100/100) and the stock is 35% of the way up its 52-week range. The weighted factor score lands at 23/100 — a bearish signal. Research only, not investment advice.
Universal leanmarket
AGIO
Agios Pharmaceuticals, Inc.
$30.55-17.94%
LEANSOFT caution / pressure
WHY
- Agios Pharmaceuticals, Inc. (AGIO) is trading at $30.55, down 17.94% since the previous close and -17.43% over the past week. Price sits below its 50-day average by 9.14%, with price momentum at 21/100 and trend velocity at 42/100. Sentiment across 8 recent headlines reads net constructive at 60/100. Volatility risk is elevated (100/100) and the stock is 35% of the way up its 52-week range. The weighted factor score lands at 23/100 — a bearish signal. Research only, not investment advice.
- Bear input: Momentum 21/100 with trend velocity 42/100 — trend is rolling over.
RISK
Signals are model output from public data, not personalized investment advice.
INVALIDATE
Invalidate on a reclaim of the session offer, catalyst relief, or model edge flipping bullish.
AI Signal
Bearish · Strong bearish edge
live data
Full public-market mode: chart history, quote, and news inputs were available.
Chart feed
Cron market chart feed
Quote/history
Six-month public chart history loaded.
News feed
8 relevant headlines found.
Signal inputs
Technical factors and news sentiment evaluated across multiple signal inputs.
News Sentiment60/100
Price Momentum21/100
Trend Velocity42/100
Volatility Risk100/100
Historical Modeling: Visualized ranges are mathematically derived from historic volatility metrics, corporate filings, and option-implied volume profiles. They represent statistical points of interest for research purposes, not financial execution commands or advice.
Why It Matters
Signal Explanation
Agios Pharmaceuticals, Inc. (AGIO) is trading at $30.55, down 17.94% since the previous close and -17.43% over the past week. Price sits below its 50-day average by 9.14%, with price momentum at 21/100 and trend velocity at 42/100. Sentiment across 8 recent headlines reads net constructive at 60/100. Volatility risk is elevated (100/100) and the stock is 35% of the way up its 52-week range. The weighted factor score lands at 23/100 — a bearish signal. Research only, not investment advice.
Analyst Engine · Specialist model ensemble
44% of trees lean bearish on AGIO
Weighted factor score across 16 signal inputs evaluating 9 features: momentum, news, volume, volatility, range, sentiment divergence, trend structure, and oscillator. Consensus and weighting applied. Each specialist bot inspects a different slice of the feature set, casts a directional vote, and contributes a confidence weight to the final score.
Engine edgeStrong bearish edgeBearish
Inputs: newsSentiment, dayChange
News positive but tape disagrees — divergence is itself a warning.
Inputs: unusualVolume, dayChange
High volume on a down-move — distribution signature.
Inputs: volatilityRisk, momentum
High volatility (100/100) without momentum support — wide path, more downside variance.
Inputs: pctOfRange, trendVelocity
Mid-range positioning — no edge from range alone.
Inputs: newsSentiment, weekChange
Sentiment 60/100 vs week change -17.4% are in agreement — no divergence edge.
Inputs: vsSma50, momentum
Price -9.1% under 50d SMA with no momentum reclaim — downtrend intact.
Inputs: momentum, trendVelocity
Composite oscillator at 32 — washed-out zone, mean-reversion candidate.
Inputs: momentum, dayChange, vsSma50
Momentum 21/100 with negative tape and price under the 50d SMA — downside continuation.
Inputs: newsSentiment, weekChange
News 60/100 and weekly change -17.4% do not create a clean follow-through read.
Inputs: unusualVolume, trendVelocity
Volume 100/100 does not show a dry-up signal.
Inputs: volatilityRisk, pctOfRange, momentum
Very high volatility (100/100) with weak momentum is a rough setup for holders.
Inputs: pctOfRange, dayChange, weekChange
Range position 35% is too middle-of-the-road to matter.
Inputs: newsSentiment, momentum, weekChange
Sentiment 60/100 and momentum 21/100 are not aligned enough for a clean read.
Inputs: vsSma50, momentum, trendVelocity
Price is still under the 50d SMA and the trend has not reclaimed control.
Inputs: momentum, trendVelocity, weekChange
Oscillator at 32 does not show a rebound edge.
Why the ensemble agrees
- High volume on a down-move — distribution signature.
- Momentum 21/100 with trend velocity 42/100 — trend is rolling over.
- High volatility (100/100) without momentum support — wide path, more downside variance.
Counter-trees
- Composite oscillator at 32 — washed-out zone, mean-reversion candidate.
Bull Case
- Composite oscillator at 32 — washed-out zone, mean-reversion candidate.
Bear Case
- Momentum 21/100 with trend velocity 42/100 — trend is rolling over.
- High volume on a down-move — distribution signature.
- High volatility (100/100) without momentum support — wide path, more downside variance.
Latest Market Headlines
Headline titles only, from the publisher named on each card. Each links to the original story.
The Globe and Mail57
AGIO Stock Surges 35% in Six Months: What's Driving It?
6/17/2011, 5:00:00 PM
Seeking Alpha69
Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade)
10/30/2026, 12:28:00 PM
Seeking Alpha47
Agios falls on review extension for Pyrukynd label expansion
10/30/2026, 7:16:00 AM
MSN60
AGIO stock slumps 25% – what’s the Novo connection?
4/20/2026, 9:31:00 AM
MSN67
AGIO beats on Q1 earnings & sales, stock up 13% on new drug momentum
4/30/2026, 11:32:00 AM
Key stats
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Market cap
- $1.82B
- 52-week range
- $46/$22.24
- Volume
- 3,094,865
- Avg volume
- 1,009,834
- Analyst 1-yr target
- $37.00
- Exchange
- NASDAQ-GS
Source: Nasdaq public quote data. Research only.
Insider trades
0 buys · 2 sells by AGIO insiders (SEC Form 4 filings)
- SELL Gheuens Sarah Chief Medical Officer · 2026-10-23$56K
- SELL Gheuens Sarah Chief Medical Officer · 2026-10-23$19K
Earnings Intelligence
Next
Nov 5, 2026
Estimate
$-1.34
Actual
$-1.69
- • Last report Jul 30, 2026 (Jun 2026): EPS $-1.69 vs $-1.86 expected, +9.14% surprise.
- • Beat estimates in 4 of the last 4 quarters.
- • Next report expected Nov 5, 2026, consensus EPS $-1.34 (Zacks estimate via Nasdaq; the company may confirm a different date).
Risk Warnings
- • Signals are model output from public data, not personalized investment advice.
- • High volatility — position sizing and stops matter more here.
- • Confirm liquidity, spreads, and your own thesis before acting.
AGIO questions
What is the MarketPicks AI signal for Agios Pharmaceuticals, Inc. stock (AGIO)?
As of Nov 1, 10:57 PM ET, the ensemble reads bearish on AGIO — bearish — 7 of 16 bots down, with 1 bull, 7 bear and 8 hold votes from 16 specialist bots. Research only, not investment advice.
What is the latest AGIO price on MarketPicks?
AGIO was $30.55 on the latest quote (Nov 1, 10:57 PM ET), -17.94% since the previous close. Quotes can be delayed.
What do the momentum and trend scores for AGIO mean?
Scores run from 0 to 100, with 50 neutral. AGIO shows momentum 21/100, trend velocity 42/100 and volatility risk 100/100, with news sentiment at 60/100.
Not financial advice. MarketPicks.ai is an impersonal research tool. AI output can be wrong. Investing involves risk of loss. Do your own research and consult a licensed professional. Full disclaimer.